What is the 411 on the New 988 Hotline?
The 988 Lifeline will connect callers with specialists trained to assist with mental health crises, including psychotic symptoms and substance...
Even after Lockdowns Eased, Pandemic Depression Persisted Across Social Classes
One year into the COVID-19 pandemic, we found that more than 1 in 5 U.S. adults reported probable depression in...
Vaccine Hesitancy is Complicating Physicians’ Obligation to Respect Patient Autonomy
Autonomy is one of the pillars of bioethics, and it is the notion that the patient has the ultimate decision-making...
The COVID-19 Pandemic Offers an Opportunity to Make a Healthy Shift in Body Ideals
The COVID-19 pandemic has changed everyday life for many people in both trivial and profound ways, including how they look...
What is the New COVID-19 Variant BA.2?
While the origin of BA.2 is still unclear, it has become the dominant strain in many countries, including India, Denmark...
Abortion Pills are Just as Safe to Prescribe Online as After an In-person Exam
When medication abortion, or abortion with pills, was introduced to the U.S. in 2000, it offered a more accessible option...
FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation
Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...
Read more